Patented Medicine Prices Review Board will hear evidence regarding alleged breach of reporting requirements for acne drugs

September 22, 2016 — Ottawa, ON — Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (the Board) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide Board Staff with the pricing and sales information required under section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations. This proceeding relates to the medicines sold under the brand names Differin, Differin XP, TactuPump, and TactuPump Forte, which are generally indicated for the treatment of acne.

The public hearing is scheduled to take place from 10:00 a.m. to 4:00 p.m. (EST) from September 26 to September 27, 2016 at the following location:

Patented Medicine Prices Review Board
Hearing Room #2, 18th floor
333 Laurier Avenue West
Ottawa, Ontario K1P 1C1

The purpose of the hearing is to receive evidence and argument of Board Staff and Galderma Canada Inc. regarding allegations that Galderma Canada Inc. is in breach of its reporting requirements.

Quick Facts

• The Patented Medicine Prices Review Board is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive.
• Patentees must file price and sales information with the Patented Medicine Prices Review Board at introduction, and twice a year afterward, for each strength of each dosage form of each patented medicine sold in Canada.
• Board Staff review the prices patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis to ensure they are not excessive.
• If the Hearing Panel of the Board finds a patentee to be in breach of its reporting requirements, it may order the patentee to provide Board Staff with the required pricing and sales information.

Related Products

• Notice of Hearing
• Notice of Application – Failure to File

Additional Links

• Patent Act (Justice Canada)
• Patented Medicines Regulations (Justice Canada)
• Status of Ongoing Proceedings (Patented Medicine Prices Review Board) 

- 30 -

Contact

Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Sofie.McCoy-Astell@pmprb-cepmb.gc.ca

TTY (telecommunications device for the hearing impaired) – 613-957-4373
Follow us on Twitter: @PMPRB_CEPMB